Streetbeat News

TCBP

TC Biopharm (Holdings) Plc

https://www.tcbiopharm.com

Industry

Biotechnology

TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom.

Open

0.78

Mkt cap

188K

Volume

27M

High

0.96

P/E Ratio

N/A

52-wk high

138.00

Low

0.56

Div yield

N/A

52-wk low

0.56

TC BioPharm has been granted European Patent Number EP3283620 for 'Modified Gamma Delta Cells And Uses Thereof' aimed at treating cancer and infectious diseases.

Portfolio Pulse from Benzinga Newsdesk

July 29, 2024 | 3:26 pm

TC BioPharm (TCBP) has dosed the sixth patient in its ACHIEVE study, which focuses on treating patients with Acute Myeloid Leukemia (AML).

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 12:03 pm

TC BioPharm (NASDAQ:TCBP) has launched a compassionate use program for its lead therapeutic, TCB008, in the UK. This program will make TCB008 available to patients, potentially accelerating its adoption and providing critical data for further development.

Portfolio Pulse from Benzinga Newsdesk

May 15, 2024 | 12:37 pm

Zeta Global Holdings Corp. (NASDAQ:ZETA) shares surged 15% in pre-market trading after reporting better-than-expected Q1 results and raising Q2 revenue guidance. Other stocks also moved significantly in pre-market trading due to various reasons including earnings reports, acquisitions, and public offerings.

Portfolio Pulse from Avi Kapoor

May 07, 2024 | 12:11 pm

TC BioPharm (NASDAQ:TCBP), a biotech firm, announced the exercise of warrants for £3.1 million in gross proceeds to fund an Acute Myeloid Leukemia trial and other expenses. The warrants allow the purchase of 1,750,000 ADSs at £1.5814 each. New warrants will also be issued, exercisable for 3,500,000 shares at £1.175 per ADS. H.C. Wainwright & Co. serves as the placement agent, with the offering expected to close by May 8, 2024.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 5:03 pm

Health care stocks experienced significant movements in Monday's intraday session, with NRX Pharmaceuticals, TC BioPharm, Outset Medical, Nanoviricides, Chemomab Therapeutics, and Titan Pharma among the gainers. Conversely, Lyra Therapeutics, GlycoMimetics, EyePoint Pharmaceuticals, Acutus Medical, Integra Lifesciences, and Helius Medical Technologies were notable losers. The movements were attributed to various factors, including earnings reports for some companies.

Portfolio Pulse from Benzinga Insights

May 06, 2024 | 4:31 pm

EyePoint Pharmaceuticals' shares plummeted by 42% after its Phase 2 PAVIA trial of DURAVYU failed to meet the primary endpoint. Conversely, XBP Europe Holdings saw a 108% surge in shares following a $40 million contract win for a transformation project. Freshpet's shares increased by 15% due to strong Q1 financial results.

Portfolio Pulse from ryanfaloona@benzinga.com

May 06, 2024 | 12:44 pm

TC BioPharm's stock price increased following the announcement of a non-binding letter of intent to acquire a company focused on developing CAR-T therapies for refractory cancers and solid tumors.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:41 pm

TC BioPharm (NASDAQ:TCBP) announced its second non-binding letter of intent in recent months to acquire a biotech company focused on CAR-T therapies for cancer. This move aligns with TCBP's M&A strategy to enhance its allogeneic gamma-delta T cell therapy platform. The acquisition target has demonstrated proof of concept for its CAR-T therapies against solid tumors and is developing treatments for autoimmune diseases. The completion of this acquisition is contingent on several factors, including financing and regulatory approvals.

Portfolio Pulse from Benzinga Newsdesk

May 06, 2024 | 12:34 pm

In Wednesday's after-market session, health care stocks saw significant movement. Trevena, Mustang Bio, SINTX Techs, Fortress Biotech, TC BioPharm, and Acutus Medical were among the gainers, with Trevena leading at a 27% increase. Conversely, TRACON Pharma, DIH Holding US, Virax Biolabs Group, Soligenix, INVO Bioscience, and ProKidney were the losers, with TRACON Pharma experiencing the largest decline at 16.6%. Market cap values varied, highlighting the volatility in the health care sector.

Portfolio Pulse from Benzinga Insights

April 17, 2024 | 8:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.